H.C. Wainwright Reiterates Buy Rating, $45 Price Target on Pliant Therapeutics (PLRX)

May 4, 2022 6:16 AM EDT Send to a Friend
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $45.00 price target on Pliant Therapeutics (NASDAQ: PLRX).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login